ALACOVID Study for Vaccinated Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-15

Study Completion Date

2022-06-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, it is hypothesized that administration of 5-ALA-Phosphate + SFC in subjects vaccinated against Covid-19 could contribute in enhancing the targeted function of the immune system, which might lead to re-activation and/or increase of the vaccination response. Thus, in the present study, we will be evaluating the safety and efficacy of 5-ALA-Phosphate + SFC in subjects receiving the Covid-19 vaccine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19

NCT05305547

SARS-CoV-2 Infection

COMPLETED PHASE3

Effect of Daily Oral Administration of Food Supplement NLC-V in Patients Diagnosed With COVID-19

NCT05226767

COVID-19

COMPLETED PHASE2

CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients

NCT04734873

Covid-19

TERMINATED PHASE3

Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.

NCT04949386

Post Acute COVID-19 Syndrome Long COVID COVID-19 Respiratory Infection

UNKNOWN PHASE2

A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19

NCT04330586

COVID-19

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Respiratory Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

An Open-Label, Pilot Study

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

150 mg 5-ALAPhosphate + SFC

2 capsules in the morning after breakfast (before 11 AM) and 1 capsule in the evening after a snack or after dinner (before 8 PM) orally with water for 21 days.

Group Type EXPERIMENTAL

150 mg 5-ALAPhosphate + SFC

Intervention Type DRUG

2 capsules in the morning after breakfast (before 11 AM) and 1 capsule in the evening after a snack or after dinner (before 8 PM) orally with water for 21 days.

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

No Description for the intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

150 mg 5-ALAPhosphate + SFC

2 capsules in the morning after breakfast (before 11 AM) and 1 capsule in the evening after a snack or after dinner (before 8 PM) orally with water for 21 days.

Intervention Type DRUG

Placebo

No Description for the intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male \& female aged ≥ 18 years and ≤70 years.
2. Subjects with documented proof of 1st dose of vaccination within 3 months of planned 2nd dose. (If government of India implements booster dose then subjects needs to have a documented proof of 2nd dose)
3. Subjects planning to have 2nd /3rd dose of COVID-19 vaccine (Covishield/ Covaxin). (If government of India implements booster dose then subjects planning to have a 3rd dose of vaccine will be included in this study)
4. Subject willing and able to provide a written informed consent

Exclusion Criteria

1. Subjects with anemia (male: \<12 g/dl, females: \<11 g/dl)
2. Subjects with more than 2.5 times upper limit of ALT \& AST parameters.
3. Subjects not willing to stop intake of any vitamin/s or mineral/s supplements during the trial except for those allowed in the study.
4. Subjects with acute symptomatic COVID-19 infection indicated by fever, dry cough and severe respiratory distress.
5. Subjects with SpO2 \< 90%.
6. Subjects with history of genetic disorders.
7. Subjects with history of:

1. Anaphylactic or allergic reaction to a previous dose of COVID-19 vaccine
2. Immediate or delayed-onset anaphylaxis or allergic reaction to vaccines or injectable therapies, pharmaceutical products, food-items etc.
8. Pregnancy \& Lactation:

a. Pregnant \& Lactating women have not been part of any COVID-19 vaccine clinical trial so far. Therefore, women who are pregnant or not sure of their pregnancy; and lactating women should not receive COVID-19 vaccine at this time
9. Provisional / temporary contraindications:

1. Persons having active symptoms of SARS-CoV-2 infection.
2. SARS-COV-2 patients who have been given anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma
3. Signs of acute infection or illness
4. Hospitalized patients due to any illness.
10. Subjects with known history (diagnosed case) of porphyria, or chronic serious liver disease, kidney disease or heart problems.
11. Subjects with frequent complaints of cold, fever, cough.
12. Subjects with irritable bowel syndrome.
13. Subjects who are frequent travelers or are planning to travel.
14. Subject has demonstrated previous intolerance of 5-ALA and/or SFC by topical or oral administration.
15. Subjects with known allergy to 5-ALA containing foods (spinach, shitake mushroom, octopus, baker's yeast, wine, vinegar, sake less).
16. Subjects on vitamin D supplements
17. Males and females of reproductive potential who have not agreed to use an adequate method of contraception during the study

1. For females, adequate birth control methods will be defined as: hormonal contraceptives, intrauterine device or double barrier contraception, i.e., condom

\+ diaphragm, condom or diaphragm + spermicidal gel or foam.
2. For males, adequate birth control methods will be defined as double barrier contraception, i.e., condom + diaphragm, condom or diaphragm + spermicidal gel or foam.
3. For females, menopause is defined as one year without menses; if in question, a follicle-stimulating hormone of \>40 U/ml must be documented. Hysterectomy, bilateral oophorectomy, or bilateral tubal ligation must be documented, as applicable.
18. Subjects who are unable or unwilling to comply with requirements of the clinical trial.
19. Participation in any other clinical trial of an experimental treatment for COVID-19.
20. Subjects having any other family member participating in this study.
21. Subjects who may be excluded at the Investigator's discretion.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No